CRISPR therapy VERVE-102 reduces cholesterol by 62% after injection
Journal NEJM published data on the drug VERVE-102: a single CRISPR injection (base editing) reduces LDL by 62% for 18 months without serious side effects. Learn details about the revolutionary therapy.
